Halozyme Therapeutics Earnings: Here’s Why Investors are Ambivalent Now
Halozyme Therapeutics, Inc. (NASDAQ:HALO) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Halozyme Therapeutics, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.17 in the quarter versus EPS of $-0.14 in the year-earlier quarter.
Revenue: Rose 59.01% to $11.83 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Halozyme Therapeutics, Inc. reported adjusted EPS loss of $0.17 per share. By that measure, the company missed the mean analyst estimate of $-0.15. It beat the average revenue estimate of $7.05 million.
Quoting Management: “With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our near term revenue drivers,” said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. “Moreover, over the next 8 weeks, we will present a first-look at clinical data from our innovative pipeline products, PEGPH20 and HTI-501.”
Key Stats (on next page)…